Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 9 April 2021, including: safety concerns for JAK inhibitors; Takeda’s R&D plans; Cigna’s psoriasis insurance program; upcoming Phase III readouts to look out for; and an overview of the global R&D pipeline.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?" - Scrip, 7 Apr, 2021.)
(Also see "Takeda Highlights Rare Neurological Disorder Programs In Wave 1" - Scrip, 6 Apr, 2021.)
(Also see "Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx" - Scrip, 6 Apr, 2021.)
(Also see "Five Phase III Data Readouts To Look Out For In Q2" - Scrip, 7 Apr, 2021.)
(Also see "COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth" - Scrip, 5 Apr, 2021.)